We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · January 04, 2022

Combination Therapy for Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Kidney International


Additional Info

Kidney International
Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis
Kidney Int. 2021 Dec 01;100(6)1316-1324, K Gulati, H Edwards, M Prendecki, TD Cairns, M Condon, J Galliford, M Griffith, JB Levy, FWK Tam, A Tanna, CD Pusey, SP McAdoo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading